71082-46-7

Usage

Uses

Used in Chemical Synthesis:
Ethyl 7-methoxyquinoline-3-carboxylate is used as a key intermediate in the synthesis of quinoline carboxylates for [application reason] the study of rhodium-catalyzed ortho C-H bond activation of arylamines. This process is significant in the development of new synthetic methods and the creation of novel chemical compounds with potential applications in various fields, such as pharmaceuticals, materials science, and agrochemicals.
Used in Pharmaceutical Research:
In the pharmaceutical industry, ethyl 7-methoxyquinoline-3-carboxylate is used as a starting material or intermediate for the development of new drugs. Its unique chemical structure allows for the exploration of its potential therapeutic properties and the possibility of creating new medications with improved efficacy and reduced side effects.
Used in Materials Science:
Ethyl 7-methoxyquinoline-3-carboxylate may also find applications in the field of materials science, where its chemical properties can be utilized to develop new materials with specific characteristics, such as improved conductivity, stability, or optical properties.
Used in Agrochemicals:
In the agrochemical industry, ethyl 7-methoxyquinoline-3-carboxylate could be employed as a building block for the synthesis of new pesticides or other agrochemical products, potentially leading to more effective and environmentally friendly solutions for crop protection and management.

Upstream product

• 63463-15-0 ethyl 4-hydroxy-7-methoxyquinoline-3-carboxylate 
• 536-90-3 m-Anisidine 
• 87-13-8 diethyl 2-ethoxymethylenemalonate 
• 56881-19-7 Diethyl 2-<(3-methoxyphenylamino)methylene>malonate 
• 64-18-6 formic acid 
• 623-47-2 propynoic acid ethyl ester 
• 77156-85-5 Ethyl 4-chloro-7-methoxyquinoline-3-carboxylate 

Downstream Products

• 474659-26-2 7-methoxyquinoline-3-carboxylic acid 
• 659730-27-5 7-hydroxyquinoline-3-carboxylic acid 

Relevant academic research and scientific papers

Rhodium-catalyzed ortho C-H bond activation of arylamines for the synthesis of quinoline carboxylates

The rhodium catalyzed annulation of anilines with alkynic esters allowing for the high-yield synthesis of quinoline carboxylates with excellent regioselectivity is described. This unprecedented reaction employs either formic acid as the C1 source and reductant or copper(ii) as the oxidant and is proposed to proceed via rhodacycle of in situ generated amide and enamine ester followed by ortho C-H activation of arylamines with rhodium as the catalyst.

A ONE POT SYNTHESIS OF 3-SUBSTITUTED QUINOLINE CARBOXYLATES AND ITS DERIVATIVES

The present invention provides a one pot, simple, cost effective and industrially feasible catalytic synthesis of quinolines or substituted quinolines from anilines with yield >80% yield. The present invention also discloses a process for the synthesis of oxolinic acid using quinolines with yield > 45%.

SUBSTITUTED NAPHTHYRIDINE AND QUINOLINE COMPOUNDS AS MAO INHIBITORS

The invention provides a chemical entity of Formula (I) wherein R1, R2, R3, Y, and n have any of the values described herein and compositions comprising such chemical entities; methods of making them; and their use in a wi

SUBSTITUTED PYRAZOLES, COMPOSITIONS CONTAINING SUCH COMPOUNDS AND METHODS OF USE

The present invention relates to substituted pyrazoles, compositions containing such compounds and methods of treatment. The compounds are glucagon receptor antagonists and thus are useful for treating, preventing or delaying the onset of type 2 diabetes

QUINAZOLINE DERIVATIVES AS ANGIOGENESIS INHIBITORS

The invention relates to the use of compounds of the formula I: wherein ring C is an 8, 9, 10, 12 or 13-membered bicyclic or tricyclic moiety which optionally may contain 1-3 heteroatoms selected independently from O, N and S; Z is -O-, -NH-, -S-, -CH2- or a direct bond; n is 0-5; m is 0-3; R represents hydrogen, hydroxy, halogeno, cyano, nitro, trifluoromethyl, C1-3alkyl, C1-3alkoxy, C1-3alkylsulphanyl, -NRR (wherein R and R, which may be the same or different, each represents hydrogen or C1-3alkyl), or RX- (wherein X and R are as defined herein; R represents hydrogen, oxo, halogeno, hydroxy, C1-4alkoxy, C1-4alkyl, C1-4alkoxymethyl, C1-4alkanoyl, C1-4haloalkyl, cyano, amino, C2-5alkenyl, C2-5alkynyl, C1-3alkanoyloxy, nitro, C1-4alkanoylamino, C1-4alkoxycarbonyl, C1-4alkylsulphanyl, C1-4alkylsulphinyl, C1-4alkylsulphonyl, carbamoyl, N-C1-4alkylcarbamoyl, N,N-di(C1-4alkyl)carbamoyl, aminosulphonyl, N-C1-4alkylaminosulphonyl, N,N-di(C1-4alkyl)aminosulphonyl, N-(C1-4alkylsulphonyl)amino, N-(C1-4alkylsulphonyl)-N-(C1-4alkyl)amino, N,N-di(C1-4alkylsulphonyl)amino, a C3-7alkylene chain joined to two ring C carbon atoms, C1-4alkanoylaminoC1-4alkyl, carboxy or a group RX (wherein X and R are as defined herein); and salts thereof, in the manufacture of a medicament for use in the production of an antiangiogenic and/or vascular permeability reducing effect in warm-blooded animals, processes for the preparation of such compounds, pharmaceutical compositions containing a compound of formula I or a pharmaceutically acceptable salt thereof as active ingredient and compounds of formula I. The compounds of formula I and the pharmaceutically acceptable salts thereof inhibit the effects of VEGF, a property of value in the treatment of a number of disease states including cancer and rheumatoid arthritis.